Annual capacity of our new coronavirus vaccine exceeds 7 billion doses

Read Time:1 Minute, 46 Second

The reporter learned from the Ministry of Industry and Information Technology Consumer Goods Industry Division, China’s regular do a good job of key medical supplies to protect the work, focusing on increasing capacity, stable production, the coordination of multiple resources, to promote the supply of medical supplies to enhance the capacity. At present, the annual production capacity of the new coronavirus vaccine exceeds 7 billion doses.

It is understood that, for the recent domestic epidemic multi-point distribution of the situation, the Ministry of Industry and Information Technology to strengthen the new coronavirus detection reagents, protective supplies, therapeutic drugs and vaccines and other key medical supplies production scheduling, close tracking and monitoring of key enterprises production and supply situation. So far, the antigen detection key production enterprises weekly production capacity of more than 500 million copies, N95 / KN95 mask key production enterprises weekly production capacity of more than 100 million, protective clothing key production enterprises weekly production capacity of more than 3 million pieces, the new coronavirus vaccine annual production capacity of more than 7 billion doses, production of more than 5.5 billion doses, to meet the needs of the current epidemic prevention and control situation.

The next step, the Ministry of Industry and Information Technology will continue to improve the production scheduling and supply of key medical supplies to strengthen the supply and demand for accurate docking to ensure timely and adequate supply; closely track the progress of new detection reagents, therapeutic drugs and vaccine development and marketing, and timely guidance to enterprises to prepare for large-scale production; support enterprises to carry out international cooperation to assist developing countries to enhance local production capacity.

In addition, will accelerate the implementation of the “14th Five-Year Plan” for the development of the pharmaceutical industry, accelerate the industrialization of innovative achievements, the pharmaceutical industry chain to strengthen the chain of complementary action, focus on weak links, support the industry chain upstream and downstream enterprises to carry out collaborative research, and continue to improve the level of pharmaceutical industry manufacturing, the construction of a number of high-standard API centralized production base.